- Home
- INAB
INAB
IN8bio Inc.
as 07-26-2024 4:00pm EST
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 37.1M | IPO Year: | 2021 |
| Target Price: | $8.83 | AVG Volume (30 days): | 140.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $2.48 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest IN8bio Inc. News
INAB Breaking Stock News: Dive into INAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Zacks Small Cap Research
a month ago
INAB: INB-100 Update at EHA24 ¡Olé!
Barrons.com
a month ago
IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking
MT Newswires
a month ago
JonesTrading Adjusts IN8bio's Price Target to $6.50 From $5, Keeps Buy Rating
GlobeNewswire
a month ago
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
GlobeNewswire
2 months ago
Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
Compare INAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INAB IN8bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.